Gland Pharma Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/x4njc4nv7n2ran16uuz2b0vf.pdf

Key Takeaways


Cenexi Turnaround: Progress, Pain & Timeline

Srinivas Sadu: "While we remain optimistic about the opportunity, I must inform all of you that Cenexi is still a few quarters away from a complete turnaround."

U.S. Market: The Quarter-by-Quarter Noise

Srinivas Sadu: "If you compared to the last year, the volume wise it's gone up by almost 30%. But if you see the previous quarter, the quantity, you can't really compare, it's almost the same, I think, gone down by 2% U.S., but it's more to do with how many batches can make on those lines. And it's more a capacity situation on a couple of brands, which impacted us a bit."

Biologics CDMO: Early Innings, Real Optionality

Srinivas Sadu: "For sure, I just mentioned, I think that also is result of this, I would say, because I think we are seeing more inbounds than compared to before. And they're looking India as a second base for a lot of companies to have to derisk themselves. So, I would say that it would benefit CDMOs in this space."

India & Rest of World: Strategic Resets


Margins: The Two-Speed Story


Regulatory & Capacity: Quiet Progress

Alain Kirchmeyer: "This line will be commissioned during the summer shutdown period of August, with commercial production slated to begin in early 2025. We anticipate this new line will significantly increase capacity, improve customer service, and generate approximately €10 million in revenue in 2025."

Guidance & Commitments

CommitmentSpecificsTimeline
Base business revenue growthMid-teens growth for full year (ex-Cenexi)FY25
Base business EBITDA marginAround 32-33%FY25
Cenexi EBITDA breakevenPositive EBITDAQ4 FY25
Cenexi full-year EBITDAPositive EBITDA for the full fiscal yearFY26
Cenexi revenue thresholdRevenue exceeding €200 million to drive EBITDA positivityFY26
Cenexi Q2 revenueApproximately two-thirds of Q1 FY25 revenue levelQ2 FY25
Heparin margin normalisationDilution from initial stock build normalisesStarting Q2 FY25
U.S. annual performanceOn track to meet beginning-of-year targetFY25
Fontenay ampoule line revenueApproximately €10 millionCalendar 2025
Biologics collaboration clarityMore clarity on commercial benefit and structure~1 quarter

Key Metrics

MetricQ1 FY25
Consolidated revenue₹1,401.7 cr, +16% YoY
Base business revenue (ex-Cenexi)₹1,013.4 cr, +14% YoY
Consolidated gross margin60%, vs 63% in Q1 FY24
Consolidated EBITDA₹265.4 cr, -11% YoY
Consolidated EBITDA margin19%, vs 25% in Q1 FY24
Base business EBITDA margin29%, vs 30% in Q1 FY24
Consolidated net profit₹143.8 cr, -26% YoY
Consolidated PAT margin10%
Base business PAT growth20% YoY
U.S. market revenue growth27% YoY
Core markets revenue share76% of total revenue, 25% YoY growth
Rest of world markets revenue share20% of total revenue, -3% YoY
India market revenue share4% of total revenue, -19% YoY
Cenexi revenue₹388.3 cr (€43 mn), +7% QoQ
Cenexi gross margin78%, improved to historical level
Cenexi EBITDA-₹28.6 cr (-€3 mn)
R&D expenditure₹48.9 cr, 5% of base business revenue
ANDAs filed during quarter8 filed, 7 approved
Total ANDA status (as of Jun 30, 2024)356 filed, 295 approved, 61 pending
Product registrations worldwide1,708
Cash and equivalents (group level)₹3,048.8 cr as of Jun 30, 2024
Net cash position₹2,743 cr, including Cenexi loans
Cash flow from operations₹427.7 cr for three months ending Jun 30, 2024, vs ₹62.9 cr in same period last year
Average cash conversion cycle148 days, vs 233 days in previous period
Capital expenditure₹63.7 cr in current fiscal year
Base business full-year revenue growth guidanceMid-teens
Base business full-year EBITDA margin guidance32%–33%
Cenexi EBITDA guidancePositive EBITDA for Q4 FY25 and positive EBITDA for next fiscal year
New Fontenay ampoule line expected revenue~€10 mn in 2025